Bills › 91st General Assembly
Relating to a review of anti-obesity medications by the department of health and human services for purposes of the medical assistance program
Sponsored by the House Health and Human Services Committee
Topics:Health careFamilies & human servicesMedicaid
Same legislation: HSB 209
Where it is now
- Done: IntroducedFebruary 19, 2025
- Done: SubcommitteeFebruary 19, 2025
- Done: House committeeFebruary 26, 2025
- Stopped: Passes the HouseDied when the General Assembly ended
- Next: Senate committeeFunnel: by March 20, 2026
- Next: Passes the Senate
- Next: To the Governor
- Next: Signed into law
Died when the session ended The 2026 session adjourned on May 3, 2026, the General Assembly’s last regular session. Bills that didn’t pass both chambers died. What’s a funnel?
What’s in it
AI summary The Department of Health and Human Services must study whether certain weight-loss medicines should be covered by Medicaid. They will look at how well these drugs work, their costs, and which people should be allowed to use them. A report with their findings and suggestions will be given to the state legislature by December 2025.1
Read the official explanation
This bill relates to the department of health and human services (HHS) review of anti-obesity medication for purposes of the medical assistance program (Medicaid). The bill requires HHS to review anti-obesity medications for effectiveness, comorbidities, cost savings, and eligibility requirements as described in the bill. HHS shall submit a report to the general assembly by December 1, 2025, containing HHS’s findings and proposed eligibility requirements.
House subcommittee
Named February 19, 2025 (as HSB 209). On February 25, 2025 it recommended passage.
Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part
Lobbying
4 for · 0 against · 5 undecided · Who →
Family tree
Study bill
91st General Assembly